UofT Libraries is getting a new library services platform in January 2021.
Learn more about the change.

Search Articles

X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (279) 279
Newspaper Article (63) 63
Book Chapter (13) 13
Patent (8) 8
Book / eBook (3) 3
Magazine Article (2) 2
Web Resource (2) 2
Book Review (1) 1
Conference Proceeding (1) 1
Reference (1) 1
Trade Publication Article (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
science & technology (145) 145
life sciences & biomedicine (140) 140
oncology (127) 127
humans (101) 101
male (56) 56
female (45) 45
respiratory system (41) 41
aged (40) 40
middle aged (39) 39
adult (36) 36
lung neoplasms - drug therapy (35) 35
lung cancer (34) 34
chemotherapy (31) 31
cancer (30) 30
carcinoma, non-small-cell lung - drug therapy (30) 30
lung neoplasms - pathology (30) 30
lung cancer, non-small cell (28) 28
carcinoma, non-small-cell lung - pathology (24) 24
neoplasm staging (24) 24
mutation (21) 21
nsclc (21) 21
surgery (21) 21
treatment outcome (21) 21
antineoplastic combined chemotherapy protocols - therapeutic use (20) 20
aged, 80 and over (19) 19
610 medicine & health (18) 18
immunotherapy (18) 18
lung neoplasms - genetics (18) 18
patients (18) 18
clinic for oncology and hematology (17) 17
hematology, oncology and palliative medicine (17) 17
lung neoplasms - therapy (17) 17
tumors (16) 16
care and treatment (15) 15
antineoplastic agents - therapeutic use (14) 14
cancer therapies (14) 14
carcinoma, non-small-cell lung - genetics (14) 14
carcinoma, non-small-cell lung - therapy (14) 14
lung neoplasms - diagnosis (14) 14
non-small cell lung carcinoma (14) 14
research (14) 14
follow-up studies (13) 13
abridged index medicus (12) 12
general & internal medicine (12) 12
analysis (11) 11
animals (11) 11
metastasis (11) 11
non-small-cell lung cancer (11) 11
prognosis (11) 11
pulmonary and respiratory medicine (11) 11
radiotherapy (11) 11
1506 (10) 10
biopsy (10) 10
carcinoma, non-small-cell lung - diagnosis (10) 10
disease-free survival (10) 10
lung neoplasms - mortality (10) 10
medicine, general & internal (10) 10
drug therapy (9) 9
health aspects (9) 9
immunohistochemistry (9) 9
lung neoplasms (9) 9
non-small cell lung cancer (9) 9
patient outcomes (9) 9
radiation therapy (9) 9
retrospective studies (9) 9
risk factors (9) 9
survival analysis (9) 9
diagnosis (8) 8
europe (8) 8
medicine & public health (8) 8
mortality (8) 8
protein kinase inhibitors - therapeutic use (8) 8
targeted therapy (8) 8
apoptosis (7) 7
carcinoma, non-small-cell lung - mortality (7) 7
carcinoma, non-small-cell lung - surgery (7) 7
crizotinib (7) 7
esmo (7) 7
lung neoplasms - surgery (7) 7
pathology (7) 7
pd-l1 protein (7) 7
pulmonary/respiratory (7) 7
small cell lung carcinoma (7) 7
switzerland (7) 7
tomography, x-ray computed (7) 7
young adult (7) 7
adenocarcinoma (6) 6
adenocarcinoma - drug therapy (6) 6
adenocarcinoma of lung (6) 6
antineoplastic agents (6) 6
biomarkers (6) 6
cisplatin - administration & dosage (6) 6
clinical trials (6) 6
cohort studies (6) 6
combined modality therapy (6) 6
consensus (6) 6
disease progression (6) 6
hematology (6) 6
hospitals (6) 6
lung cancer, small cell (6) 6
more...
Library Location Library Location
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Journal of clinical oncology, ISSN 1527-7755, 06/2013, Volume 31, Issue 16, pp. 1997 - 2003
Journal Article
Journal Article
The New England journal of medicine, ISSN 1533-4406, 08/2017, Volume 377, Issue 9, pp. 829 - 838
Alectinib, a potent ALK tyrosine kinase inhibitor, was more effective and somewhat less toxic than crizotinib when used as primary therapy in patients with ALK... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Lung Neoplasms - drug therapy | Pyrazoles - therapeutic use | Follow-Up Studies | Lung Neoplasms - mortality | Humans | Middle Aged | Male | Antineoplastic Agents - therapeutic use | Protein Kinase Inhibitors - adverse effects | Central Nervous System Neoplasms - secondary | Young Adult | Pyridines - adverse effects | Anaplastic Lymphoma Kinase | Antineoplastic Agents - adverse effects | Aged, 80 and over | Receptor Protein-Tyrosine Kinases - antagonists & inhibitors | Adult | Female | Receptor Protein-Tyrosine Kinases - analysis | Pyrazoles - adverse effects | Pyridines - therapeutic use | Crizotinib | Carbazoles - adverse effects | Kaplan-Meier Estimate | Carcinoma, Non-Small-Cell Lung - mortality | Disease-Free Survival | Animals | Piperidines - therapeutic use | Protein Kinase Inhibitors - therapeutic use | Piperidines - adverse effects | Intention to Treat Analysis | Carbazoles - therapeutic use | Carcinoma, Non-Small-Cell Lung - drug therapy | Central Nervous System Neoplasms - drug therapy | Drugs | Care and treatment | Analysis | Comparative analysis | Lung cancer, Non-small cell | Health aspects | Systemic diseases | Toxicity | Lung cancer | Central nervous system | Non-small cell lung carcinoma | Oncology | Nervous system | Metastasis | Radiation therapy | Patients | Lymphoma | Cancer therapies | Survival | Mutation | Protein-tyrosine kinase | Drug dosages | Tumors | Index Medicus | Abridged Index Medicus
Journal Article
The New England journal of medicine, ISSN 1533-4406, 06/2017, Volume 376, Issue 25, pp. 2415 - 2426
Journal Article
The New England journal of medicine, ISSN 1533-4406, 11/2019, Volume 381, Issue 21, pp. 2020 - 2031
Patients with advanced non–small-cell lung cancer with a PD-L1 expression level of 1% or more of tumor cells were randomly assigned to receive nivolumab plus... 
Medicine, General & Internal | Life Sciences & Biomedicine | General & Internal Medicine | Science & Technology | Antineoplastic Agents, Immunological - administration & dosage | Lung Neoplasms - drug therapy | Lung Neoplasms - mortality | Humans | Lung Neoplasms - metabolism | Middle Aged | Carcinoma, Non-Small-Cell Lung - metabolism | Antineoplastic Combined Chemotherapy Protocols - adverse effects | Male | Ipilimumab - adverse effects | Nivolumab - adverse effects | Carcinoma, Non-Small-Cell Lung - mortality | Antineoplastic Agents, Immunological - adverse effects | B7-H1 Antigen - metabolism | Antineoplastic Combined Chemotherapy Protocols - therapeutic use | Survival Analysis | Aged, 80 and over | Adult | Female | Aged | Carcinoma, Non-Small-Cell Lung - drug therapy | Ipilimumab - administration & dosage | Nivolumab - administration & dosage | Lung cancer, Non-small cell | Drug therapy | Patient outcomes | Ipilimumab | Testing | Small cell lung carcinoma | Lung cancer | Non-small cell lung carcinoma | Oncology | Cancer therapies | Chemotherapy | Immunotherapy | PD-L1 protein | Biomarkers | Clinical medicine | Mutation | Drug dosages | Apoptosis | Tumors | Index Medicus | Abridged Index Medicus | B7-H1 Antigen | Carcinoma, Non-Small-Cell Lung | Antineoplastic Combined Chemotherapy Protocols | Cellular Biology | Lung Neoplasms | Life Sciences | Antineoplastic Agents, Immunological | Nivolumab
Journal Article
World journal of surgery, ISSN 0364-2313, 2/2016, Volume 40, Issue 2, pp. 373 - 379
Journal Article